Self-Assembled Nano-PROTACs for Targeted Protein Degradation in Cancer Therapy
- 1School of Pharmacy, Anhui Medical University, Hefei 231200, China
Abstract
Proteolysis-targeting chimeras (PROTACs) induce target protein ubiquitination and proteasomal degradation via recruitment of E3 ubiquitin ligases, enabling event-driven intervention against “undruggable” targets, drug-resistant proteins, and non-catalytic scaffolding functions. Conventional PROTACs, however, face limitations including high molecular weight, poor solubility and membrane permeability, unfavorable pharmacokinetics, limited tissue selectivity, and the hook effect. Self-assembled Nano-PROTACs allow direct nanostructure formation from intact PROTACs, prodrugs, or functional modules, and permit spatiotemporal activation by tumor microenvironment or exogenous stimuli. This review systematically examines four assembly paradigms—carrier-free co-assembly, amphiphilic conjugates, peptide- and nucleic acid-programmed assembly, and split intracellular systems—and positions stimuli-responsiveness as a cross-architectural activation hallmark. Representative studies across cancer types are categorized to analyze how self-assembled Nano-PROTACs intervene in key oncogenic processes, with comparisons of target selectivity, activation mechanisms, degradation evidence, and antitumor efficacy. Finally, clinical translation requirements are discussed regarding structure–assembly–degradation relationships, safety, quality control, and scalable manufacturing, aiming to facilitate further research and clinical development of self-assembled Nano-PROTACs in cancer therapy.
Related
- Synthesis and biological evaluation of Retro-2-based PROTACs reveal PEG-linker length and warhead impact on GSPT1 degradation
- A protein–foldamer supramolecular synthon for self-assembled hybrid architectures
- Carrier-free self-assembled nanodrugs in cancer therapy: a systematic scoping review and evidence map of molecular architecture, drug resistance, and translation-relevant reporting
- Protein-State Editing through Proximity-Induced Targeted Delactylation
- Radiopharmaceuticals and theranostics: reshaping cancer diagnosis and therapy with targeted radionuclides
BibTeX
@article{dai2026selfassembled,
title = {{Self-Assembled Nano-PROTACs for Targeted Protein Degradation in Cancer Therapy}},
author = {Jiahui Dai and Yang Liu and Xueya Wang and Xinping Zhou and Changrui Xie and Yong Jin},
journal = {Molecules},
year = {2026},
month = nov,
doi = {10.3390/molecules31214024},
url = {https://www.mdpi.com/1420-3049/31/21/4024},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Self-Assembled Nano-PROTACs for Targeted Protein Degradation in Cancer Therapy
AU - Jiahui Dai
AU - Yang Liu
AU - Xueya Wang
AU - Xinping Zhou
AU - Changrui Xie
AU - Yong Jin
PY - 2026
DA - 2026/11/08
JO - Molecules
DO - 10.3390/molecules31214024
UR - https://www.mdpi.com/1420-3049/31/21/4024
AB - Proteolysis-targeting chimeras (PROTACs) induce target protein ubiquitination and proteasomal degradation via recruitment of E3 ubiquitin ligases, enabling event-driven intervention against “undruggable” targets, drug-resistant proteins, and non-catalytic scaffolding functions. Conventional PROTACs, however, face limitations including high molecular weight, poor solubility and membrane permeability, unfavorable pharmacokinetics, limited tissue selectivity, and the hook effect. Self-assembled Nano-PROTACs allow direct nanostructure formation from intact PROTACs, prodrugs, or functional modules, and permit spatiotemporal activation by tumor microenvironment or exogenous stimuli. This review systematically examines four assembly paradigms—carrier-free co-assembly, amphiphilic conjugates, peptide- and nucleic acid-programmed assembly, and split intracellular systems—and positions stimuli-responsiveness as a cross-architectural activation hallmark. Representative studies across cancer types are categorized to analyze how self-assembled Nano-PROTACs intervene in key oncogenic processes, with comparisons of target selectivity, activation mechanisms, degradation evidence, and antitumor efficacy. Finally, clinical translation requirements are discussed regarding structure–assembly–degradation relationships, safety, quality control, and scalable manufacturing, aiming to facilitate further research and clinical development of self-assembled Nano-PROTACs in cancer therapy.
SN - 1420-3049
ER -